IN THE UNITED STATES DISTRICT COURT

KELLYN CLAY,
  Plaintiff,

v.

UNITED STATES OF AMERICA,
by and through its agencies including but not limited to
the Central Intelligence Agency (CIA), Department of Defense (DoD),
and Department of Justice (DOJ),

and

WILLIAM ALTON CLAY,
individually and in his capacity as executor of the Estate of Eugenia Clay Head,

and

PALANTIR TECHNOLOGIES INC.,
a private defense contractor headquartered in Denver, Colorado,

and

JOHN DOE CONTRACTING AGENCIES AND AFFILIATES,
whose names and identities are presently unknown,

and

AMAZON.COM, INC.,
a multinational e-commerce corporation headquartered in Seattle, Washington,

and

REV.COM, INC.,
a transcription and captioning services company headquartered in Austin, Texas,

and

PAPERBOY MARKETING,
a flyer distribution company operating in the Twin Cities under successive ownership during the period of Plaintiff’s employment,

and

ELLIE FAMILY SERVICES, n/k/a ELLIE MENTAL HEALTH, a private mental health services corporation headquartered in Mendota Heights, Minnesota,
  Defendants.

⸻

PLAINTIFF’S COMBINED SET OF REQUESTS FOR PRODUCTION TO DEFENDANT PALANTIR TECHNOLOGIES INC.

Definitions
	1.	“WO99/24578” refers to international patent publication WO 99/24578 and any related filings, continuations, or derivative works.
	2.	“SEQ ID NO:650” refers to the specific protein sequence disclosed therein, as well as any fragments or derivatives thereof.
	3.	“Antigenic determinant” refers to any portion of a peptide or protein capable of eliciting an immune response.
	4.	“Implant array” refers to any hardware, software, or biological system associated with Plaintiff’s surveillance or neuromodulation.

⸻

REQUESTS FOR PRODUCTION
	1.	Produce all documents, records, or files maintained by Palantir referencing WO99/24578, SEQ ID NO:650, or related Neisseria protein fragments.
	2.	Produce all documents describing or analyzing the use of bacterial peptides or antigens (including SEQ ID NO:650) in connection with:
a. Neurological modulation or disorders of the nervous system;
b. Anti-inflammatory or analgesic applications;
c. Behavioral surveillance, anomaly classification, or implant-array interaction.
	3.	Produce all communications or contracts between Palantir and any government agency, defense contractor, pharmaceutical company, or research institution concerning WO99/24578, SEQ ID NO:650, or derivatives thereof.
	4.	Produce all internal memoranda, reports, or presentations analyzing the use of Neisseria-derived protein fragments as:
a. Adjuvants or immunomodulators;
b. Vectors for implant-array calibration;
c. Agents for covert delivery via food, water, or environmental exposure.
	5.	Produce all documents reflecting data models, simulations, or predictive analytics involving Plaintiff and any exposure to Neisseria-derived peptides or antigenic fragments, including SEQ ID NO:650.
	6.	Produce all records of adverse event monitoring or human subject outcomes related to exposure to such fragments, including but not limited to neurological, immunological, or behavioral effects.
